RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present a corporate update and company overview at the following conferences: Wells Fargo 2020
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc.. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present a corporate update and company overview at the following conferences:
- Wells Fargo 2020 Virtual Healthcare Conference, September 10, 2020 at 2:40 p.m. EDT
- H.C. Wainwright 22nd Annual Global Investment Conference, September 15, 2020 at 11:00 a.m. EDT
- 2020 Cantor Virtual Healthcare Conference, September 16, 2020 at 1:20 p.m. EDT
Live webcasts and audio archives of the presentations may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations. Please connect to the website 10 minutes prior to the presentations to ensure adequate time for any software downloads that may be necessary to listen to the webcast.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including hematopoietic progenitor kinase 1 (HPK1) and general control nonderepressible 2 (GCN2), that are in the discovery stage of development.
RAPT Media Contact:
Angela Bitting
media@rapt.com
(925) 202-6211
RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com
